daratumumab
Sign in to saveDaratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 458638612
- Drug.type
- mab
- Drug.image
- Daratumumab CD38 7DHA.png
- Drug.caption
- Fab fragment of daratumumab (teal/green) binding CD38 (pale pink). From PDB entry
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- CD38
- Drug.tradename
- Darzalex, Darzalex SC
- Drug.MedlinePlus
- a616002
- Drug.DailyMedID
- Daratumumab
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- Intravenous, subcutaneous
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- FC01
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
via Wikipedia infobox
Research
2,588 papers- Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.The New England journal of medicine · 2025
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.The New England journal of medicine · 2019
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.The New England journal of medicine · 2016
- Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.Clinical pharmacokinetics · 2023
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.The New England journal of medicine · 2016
via PubMed
~9 min read
Encyclopedic overview
10 sectionsContents
- Medical uses
- Side effects
- Interactions
- With blood compatibility testing
- With flow cytometry testing
- Pharmacology
- Mechanism of action
- Economics
- History
- References
Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.
Daratumumab was granted breakthrough therapy drug status in 2013, for multiple myeloma. It was granted orphan drug status for multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma.
Excerpted from Wikipedia’s “daratumumab” article, available under the CC BY-SA 4.0 licence.